JP2024521105A - 肺癌の処置用組成物及び方法 - Google Patents

肺癌の処置用組成物及び方法 Download PDF

Info

Publication number
JP2024521105A
JP2024521105A JP2023571866A JP2023571866A JP2024521105A JP 2024521105 A JP2024521105 A JP 2024521105A JP 2023571866 A JP2023571866 A JP 2023571866A JP 2023571866 A JP2023571866 A JP 2023571866A JP 2024521105 A JP2024521105 A JP 2024521105A
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
nsclc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521105A5 (https=
JPWO2022248478A5 (https=
Inventor
サード，アンソニー ジャーコウスキー，ザ
デニス，フィリップ
トラーニ，レオ
ニュートン，マイケル
シャイア，ノラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2024521105A publication Critical patent/JP2024521105A/ja
Publication of JP2024521105A5 publication Critical patent/JP2024521105A5/ja
Publication of JPWO2022248478A5 publication Critical patent/JPWO2022248478A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023571866A 2021-05-24 2022-05-24 肺癌の処置用組成物及び方法 Pending JP2024521105A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192217P 2021-05-24 2021-05-24
US63/192,217 2021-05-24
PCT/EP2022/064061 WO2022248478A1 (en) 2021-05-24 2022-05-24 Compositions and methods for treating lung cancer

Publications (3)

Publication Number Publication Date
JP2024521105A true JP2024521105A (ja) 2024-05-28
JP2024521105A5 JP2024521105A5 (https=) 2025-06-03
JPWO2022248478A5 JPWO2022248478A5 (https=) 2025-06-03

Family

ID=82100132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571866A Pending JP2024521105A (ja) 2021-05-24 2022-05-24 肺癌の処置用組成物及び方法

Country Status (11)

Country Link
US (1) US20240254235A1 (https=)
EP (1) EP4347038A1 (https=)
JP (1) JP2024521105A (https=)
KR (1) KR20240012413A (https=)
CN (1) CN117425493A (https=)
AU (1) AU2022281992A1 (https=)
BR (1) BR112023023833A2 (https=)
CA (1) CA3219960A1 (https=)
IL (1) IL308530A (https=)
TW (1) TW202313107A (https=)
WO (1) WO2022248478A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120936347A (zh) * 2023-04-14 2025-11-11 阿斯利康(瑞典)有限公司 非小细胞肺癌的治疗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
US20190276543A1 (en) * 2018-03-08 2019-09-12 Astrazeneca Pharmaceuticals Lp Compositions and methods for treating late stage lung cancer
BR112022022304A2 (pt) * 2020-05-04 2022-12-20 Merck Sharp & Dohme Llc Métodos para tratar câncer usando uma combinação de um antagonista pd-1, uma quimiorradioterapia e um inibidor de parp

Also Published As

Publication number Publication date
IL308530A (en) 2024-01-01
AU2022281992A1 (en) 2024-01-04
EP4347038A1 (en) 2024-04-10
WO2022248478A1 (en) 2022-12-01
KR20240012413A (ko) 2024-01-29
US20240254235A1 (en) 2024-08-01
BR112023023833A2 (pt) 2024-01-30
CA3219960A1 (en) 2022-12-01
TW202313107A (zh) 2023-04-01
CN117425493A (zh) 2024-01-19

Similar Documents

Publication Publication Date Title
US11273219B2 (en) Toxicity management for anti-tumor activity of CARs
CN113661180B (zh) Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
JP2024521105A (ja) 肺癌の処置用組成物及び方法
CN113372444A (zh) 通过抑制胞外核苷酸酶和抗体-介导靶向吞噬预防或逆转t-细胞衰竭的组合物与用途
WO2024150177A1 (en) Treatment methods for solid tumors
US20220073622A1 (en) Compositions and Methods for Treating Late Stage Lung Cancer
US20260115284A1 (en) Toxicity management for anti-tumor activity of cars
AU2018412532B2 (en) Compositions and methods for treating late stage lung cancer
HK40116181A (en) Toxicity management for anti-tumor activity of cars
HK40116181B (en) Toxicity management for anti-tumor activity of cars
HK40069741A (en) Toxicity management for anti-tumor activity of cars
HK40069741B (en) Toxicity management for anti-tumor activity of cars
HK40039113A (en) Toxicity management for anti-tumor activity of cars
HK1253365B (en) Toxicity management for anti-tumor activity of cars
EA041322B1 (ru) Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов (car)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250523